Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer
JNCI: Journal of the National Cancer Institute · 2023
DOI: 10.1093/jnci/djad142 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Kai Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Science and Technology Council, National Health Research Institute, Center of Precision Medicine.
Abstract (Originalsprache)
Background
Osimertinib is the first-line therapy for patients with non-small cell lung cancer harboring epidermal growth factor receptor–activating alterations. Although osimertinib has been shown to elicit profound patient responses, cancer cells frequently develop additional alterations that sustain their proliferation capacity. This acquired resistance represents a substantial hurdle in precision medicine for patients with lung cancer.
Methods
The biological and cellular properties of the G-quadruplex ligand BMVC-8C3O and its anticancer activities were evaluated in non-small cell lung carcinomas. In addition, combined treatment with BMVC-8C3O and osimertinib was evaluated for its effects on the growth of osimertinib-resistant tumors in vivo.
Results
We demonstrate that BMVC-8C3O effectively suppresses c-FOS expression by stabilizing G-rich sequences located at the c-FOS promoter. The suppression c-FOS expression by BMVC-8C3O increases the sensitivity of acquired resistant cancer cells to osimertinib. Combining BMVC-8C3O and osimertinib has a synergistic effect in inhibiting the growth of acquired resistant cancers both in vitro and in mouse models. The combined inhibitory effect is not limited to BMVC-8C3O, either: several G-quadruplex ligands show varying levels of inhibition activity. We also show that simultaneous inhibition of both the c-FOS and PI3K/AKT pathways by BMVC-8C3O and osimertinib synergistically inhibits the growth of acquired resistant cancer cells.
Conclusion
These findings unveil a synthetic lethal strategy to prevent and inhibit epidermal growth factor receptor–altered lung cancers with acquired osimertinib resistance. G-quadruplex ligands have the potential to be integrated into current osimertinib-based treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung, Taiwan.
- Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei, Taiwan.
ORCID-Profile: Ta-Chau Chang, Jing-Jer Lin
Förderung
- National Science and Technology Council
- National Health Research Institute
- Center of Precision Medicine
- Featured Areas Research Center Program
- Higher Education Sprout
- Ministry of Education in Taiwan
Zitieren
APA
Lu, K., Wang, H. C., Tu, Y. C., Chang, C. C., Lou, P. J., Chang, T. C., & Lin, J. J. (2023). Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad142
Vancouver
Lu K, Wang HC, Tu YC, Chang CC, Lou PJ, Chang TC, et al. Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djad142
BibTeX
@article{Lu2023,
author = {Lu, Kai and Wang, Hsin-Chiao and Tu, Yi-Chen and Chang, Cheng-Chung and Lou, Pei-Jen and Chang, Ta-Chau and Lin, Jing-Jer},
title = {Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2023},
doi = {10.1093/jnci/djad142}
}
EUVIMED